Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...

HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced promising topline data from its Phase 2b ANTHEM-UC clinical trial evaluating icotrokinra (JNJ-2113) as a treatment for moderately to severely active ...

Icotrokinra met all primary endpoints in the studies, demonstrating significant skin clearance and clinical remission.

Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ...

Protagonist Therapeutics, Inc. PTGX announced positive top-line data from the phase IIb ANTHEM-UC study, which evaluated ...

Johnson & Johnson announced new icotrokinra, JNJ-2113, data from its comprehensive Phase 3 clinical program and the start of the first-ever ...

Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...

GlobalData predicts that icotrokinra will reach blockbuster status in 2029, with the drug forecast to generate sales of ...

Protagonist Therapeutics (PTGX) announced topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...

Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...

On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra ...